Integer (ITGR) to Release Earnings on Thursday

Integer (NYSE:ITGR) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect Integer to post earnings of $1.57 per share and revenue of $464.37 million for the quarter. Integer has set its FY 2025 guidance at 6.150-6.510 EPS.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, April 24th. The medical equipment provider reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Integer had a net margin of 4.38% and a return on equity of 11.95%. The company had revenue of $437.39 million for the quarter, compared to analysts’ expectations of $428.51 million. During the same quarter in the prior year, the company posted $1.14 earnings per share. Integer’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, analysts expect Integer to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Integer Trading Down 0.2%

NYSE ITGR opened at $117.15 on Thursday. The stock has a market capitalization of $4.09 billion, a P/E ratio of 55.52, a PEG ratio of 1.01 and a beta of 0.98. Integer has a 12 month low of $104.93 and a 12 month high of $146.36. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.40 and a quick ratio of 2.14. The firm’s 50-day moving average is $119.86 and its two-hundred day moving average is $124.72.

Insider Buying and Selling at Integer

In other Integer news, Director Donald J. Spence sold 14,739 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total value of $1,774,280.82. Following the transaction, the director directly owned 18,781 shares in the company, valued at $2,260,856.78. This represents a 43.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joseph W. Dziedzic sold 338,975 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the transaction, the chief executive officer owned 47,000 shares in the company, valued at $5,788,990. This represents a 87.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 362,434 shares of company stock worth $44,577,115 over the last three months. Insiders own 2.16% of the company’s stock.

Hedge Funds Weigh In On Integer

Hedge funds have recently added to or reduced their stakes in the stock. United Services Automobile Association acquired a new stake in shares of Integer in the first quarter valued at approximately $258,000. Jones Financial Companies Lllp boosted its holdings in shares of Integer by 79,888.9% in the first quarter. Jones Financial Companies Lllp now owns 7,199 shares of the medical equipment provider’s stock valued at $850,000 after acquiring an additional 7,190 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Integer by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,515 shares of the medical equipment provider’s stock valued at $2,539,000 after acquiring an additional 837 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Integer by 4.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,316 shares of the medical equipment provider’s stock worth $12,900,000 after purchasing an additional 4,873 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Integer by 2,408.8% during the first quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock worth $14,531,000 after purchasing an additional 118,224 shares during the period. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ITGR. KeyCorp reduced their price target on shares of Integer from $154.00 to $145.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. Truist Financial set a $150.00 price target on shares of Integer and gave the stock a “buy” rating in a research report on Friday, April 25th. Raymond James Financial increased their price target on shares of Integer from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Friday, April 25th. Wall Street Zen raised shares of Integer from a “sell” rating to a “hold” rating in a research report on Monday, May 19th. Finally, Citigroup raised shares of Integer from a “hold” rating to a “strong-buy” rating and increased their price target for the stock from $133.00 to $140.00 in a research report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $146.25.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.